Loading
Turned anaplastic thyroid cancer, once measured in months, into a treatable disease with BRAF-targeted therapy and neoadjuvant strategies.
Maria Cabanillas led the anaplastic thyroid cancer work within the ROAR basket trial that won dabrafenib plus trametinib approval for BRAF V600E-mutant disease, and pioneered neoadjuvant BRAF/MEK inhibition to make previously unresectable tumours operable, which has raised one-year survival in her centre's series from near zero to above 50%. She leads the anaplastic thyroid cancer programme at MD Anderson.
Shares ROAR (anaplastic thyroid cancer cohort), MD Anderson Cancer Center, BRAF, Thyroid cancer.
Shares Thyroid cancer, Small-molecule kinase inhibitors and the tag thyroid.
Shares Thyroid cancer, Small-molecule kinase inhibitors and the tag thyroid.
Shares Thyroid cancer, Small-molecule kinase inhibitors and the tag thyroid.
Shares MD Anderson Cancer Center, BRAF, Small-molecule kinase inhibitors and the tag braf.
Shares MD Anderson Cancer Center, Small-molecule kinase inhibitors.
Shares BRAF, Thyroid cancer and the tag braf.
Shares Thyroid cancer and the tag thyroid.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/